Sera Prognostics (SERA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$70,000.00

Revenue (quarter)

$30,000.00

Revenue growth (year over year)

+76.47%

Gross profit (trailing twelve months)

−$105,000.00

Gross margin

−150.00%

Net income (trailing twelve months)

−$33.2M

Net income (quarter)

−$9.1M

Net income growth (year over year)

−13.58%

Net margin

−47475.71%

Return on equity

−45.03%

EPS (trailing twelve months)

−$0.66

Book value per share

$1.51

P/E (trailing twelve months)

—

Price to book

1.36

Debt to assets

31.54%

Payout ratio

—

Dividend yield

—

Company profile

Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

• Is Sera Prognostics (SERA) profitable?

  No. Sera Prognostics reported a net loss of $33.2M over the trailing twelve months.

• How much revenue does Sera Prognostics (SERA) make?

  Sera Prognostics generated $70,000.00 in revenue over the trailing twelve months, up 76.47% year over year.

• How do I buy stock in Sera Prognostics (SERA)?

  SERA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.